business
Jump to
8 Results Found
  • Hope to complete merger formalities by October end: Shasun Aug 11, 2015 12:33 PM IST

    Hope to complete merger formalities by October end: Shasun

    Abhaya Kumar, MD at Shasun Pharmaceuticals said the company's merger with Strides will be completed as soon as court approvals of the latter are in place. He is sure the merged entity will be effective from April 1 2015 itself.

  • Ranbaxy loses Valcyte exclusivity: An analysis Nov 07, 2014 10:14 AM IST

    Ranbaxy loses Valcyte exclusivity: An analysis

    Ranbaxy has first-to-file status, meaning eligibility for six months of generic sales exclusivity for both AstraZeneca's heartburn drug Nexium & Roche's antiviral drug Valcyte drugs. However, the final approvals for these drugs were delayed because of the compliance issues at Ranbaxy's plants.

  • To clock Rs 1500cr in revenues for 2013-14: Shasun Pharma Mar 22, 2013 05:01 PM IST

    To clock Rs 1500cr in revenues for 2013-14: Shasun Pharma

    Shasun Pharmaceuticals has big capacity expansion plans for 2013-14. Speaking to CNBC-TV18, managing director Abhaya Kumar says the company is planning an investment of more than Rs 250 crore towards achieving this aim.

  • UK biz strong; see FY13 revenue at Rs 1,200cr: Shashun Dec 31, 2012 02:45 PM IST

    UK biz strong; see FY13 revenue at Rs 1,200cr: Shashun

    Shasun Pharma is one of the key suppliers to Vertex for Hepatitis C drug -Incivek, which has received a US Food & Drug Administration (USFDA) 'Black Box' warning. This warning indicates that if one gets severe rash symptoms then the drug should be stopped using immediately.

  • Capacity debottlenecking led to growth: Shasun Pharma May 25, 2012 03:54 PM IST

    Capacity debottlenecking led to growth: Shasun Pharma

    Abhaya Kumar, managing director, Shasun Pharmaceuticals Ltd says that capacity debottlenecking and higher customer demand contributed to 40% y-o-y growth. He also says that the company expects 25% growth in EPS of the company in FY13.

  • Shasun Pharma plans Rs 250cr expansion Mar 23, 2012 11:26 AM IST

    Shasun Pharma plans Rs 250cr expansion

    In an interview to CNBC-TV18, Abhaya Kumar, managing director of Shasun Pharmaceuticals says, the company has huge expansion plans. “Shasun is on a very high expansion spree now, investing more than Rs 250 crore in Vizag and in other places. We have raised Rs 50 crore,” he adds.

  • Shasun Pharma expects 40-50% topline growth in FY12 Oct 04, 2011 02:35 PM IST

    Shasun Pharma expects 40-50% topline growth in FY12

    Abhaya Kumar, managing director of Shasun Pharmaceuticals expects the company's topline to grow 40-50% in FY12. He told CNBC-TV18 in an interview that their confirmed orders for third and fourth quarter are very strong.

  • Shasun Chem to launch 'Hepatitis C' in June-July 2012 Jan 05, 2011 01:33 PM IST

    Shasun Chem to launch 'Hepatitis C' in June-July 2012

    The supply on the Hepatitis C drug to Vertex by Shasun Chemicals is set to take off earlier than anticipated. "Commercial supplies have already started and this year we are preparing for the launch," says Vimal Kumar, Managing Director of Shasun Chemicals, in an exclusive interview with CNBC-TV18.

Sections